Cardiol Therapeutics (CRDL) Cash & Equivalents (2020 - 2026)

Cardiol Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 5.31% year-over-year to $20.2 million; the trailing twelve-month figure through Mar 2026 stood at $20.2 million (down 5.31% YoY), and the FY2025 full-year result was $15.4 million, down 29.84% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $20.2 million, up from $15.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $66.2 million in Q1 2022, with the low at $13.1 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $34.7 million across 5 years, with a median of $25.7 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 497.73% — and 2025, when it slumped 48.58%.
• Cardiol Therapeutics' Cash & Equivalents stood at $43.8 million in 2022, then slumped by 41.43% to $25.7 million in 2023, then fell by 14.68% to $21.9 million in 2024, then retreated by 29.84% to $15.4 million in 2025, then surged by 31.4% to $20.2 million in 2026.
• The last three Cash & Equivalents figures came in at $20.2 million (Q1 2026), $15.4 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.